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Abstract: Effect of cyclosporin A (CsA) in a therapeutic concentration, on the expression of
cytochrome P450 genes (CYPs), was investigated in normal human dermal fibroblast cells.
The expression of 57 genes, encoding cytochrome P450 isoforms, was estimated using the microarray
method. Amongst 396 normalized fluorescence signals related to cytochrome P450 activity, only 91
were strictly connected to CYPs and were analyzed using two methods: a self-organizing feature
map of artificial neural networks and typical statistical analysis with significance level at p ≤ 0.05.
Comparing the samples from fibroblasts cultured with CsA and those cultured without, up-regulated
changes of CYP19A1, 1B1, 7A1, 7F1, 17A1 and down-regulated 2D6 gene expression were observed.
The mRNAs with increased changes were in the same neuron of the self-organizing feature
map. All distinguished CYPs encode monooxygenases, which plays an important role in steroids
biosynthesis and metabolism. Based on the obtained results, we can conclude that CsA in therapeutic
concentration changes the expression profile of CYPs in human dermal fibroblasts, especially affecting
genes linked to steroids synthesis and/or metabolism. It shows the potential mechanism of action of
CsA in human dermal fibroblast cells.
Keywords: cyclosporin A; cytochrome P450 gene; fibroblasts; microarray; MTT test; SOFM
1. Introduction
Cyclosporin A (CsA) is a classic immunosuppressive drug used, not only to prevent organ or
tissue rejection, but also in many immunologically-mediated diseases, for example, atopic dermatitis,
pyoderma gangrenosum, pemphigus, psoriasis, rheumatoid arthritis and dry eye [1–3]. There are good
effects in patient treatment in the aforementioned diseases even in oral doses [4]. CsA is metabolized
by cytochrome P450 (CYP), mainly by the isoform CYP3A4; it also works as an inhibitor of 3A4, 2C19
and 2D6 in human liver microsomes [5].
Cytochrome P450 is a large, multifunctional superfamily of 57 genes encoding monooxygenases,
which catalyze the conversion of many endobiotics and xenobiotics and have a strong clinical
significance [6]. It also produces chemicals essential for homeostasis, as well as bile acids, cholesterol,
steroids, lipids, vitamin D, retinoids, and biogenic amines. CYPs are involved in the metabolism of most
drugs, chemicals and environmental pollutants, as well as endogenous substances [6,7]. The expression
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of CYP is tissue and organ selective [8]. Expression of different CYPs has been stated in cultured
keratinocytes, Langerhans cells, fibroblasts and melanocytes [9].
CYP’s activity can be induced or inhibited by multiple endogenous and exogenous
compounds [10]. Changes in expression of CYP genes in various skin models and cells were
observed under influence of many different xenobiotics [11]. Human dermal cells are capable of
metabolizing CsA [12]. Little is known about the effects of CsA on the cytochrome P450 family
in human dermal fibroblasts. After oral administration, CsA reduces symptoms of psoriasis;
however, it also plays a predominant role in the pathophysiology of nonmelanoma skin cancer
in kidney transplant recipients [13]. Human skin fibroblasts are vital machinery for local production,
conversion, metabolism and/or inactivation of many endogenic substances such as neurotransmitters,
neuropeptides and typical hormones; cytochrome P450 is a key enzyme in these reactions [14,15].
This makes dermal fibroblasts a relevant model to investigate these genes under the influence of
therapeutic CsA concentration. To enable a wide and accurate view of the cytochrome P450 family
gene expression in human dermal fibroblasts, a microarray was used as a method of choice. A neural
network of self-organizing feature maps was used to analyze the results, and these were confirmed by
classical methods. The use of this allowed to select only the CYPs, which are activated by CsA in the
dermal fibroblasts.
Thus, the aim of this study was to estimate the effect of CsA on the CYP’s expression in normal
human dermal fibroblast cells.
2. Results
The examined amounts of CsA (in the tested range of concentrations) had not shown a toxic effect
on fibroblasts in MTT (Microculture Tetrazolium Test) test and results are presented in Figure 1.
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are showed as percent of  the absorbance  in control samples, mean ± SD; and  lack of significance, 
>0.05). 
Based on  these  results, a  concentration of 100 ng per  1 mL of medium was used  for  future 
analysis, which was both comparable to the standard therapeutic dose in patients’ blood as well as 
nontoxic. 
The obtained gene expression results were used to perform two analyses. The first approach was 
by creating clusterization with a Kohonen map (SOFM) [16], and the second by classical statistical 
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Figure 1. Cell viability after exposure to cyclosporin A (CsA). Legend: Exposure to different
concentration of CsA for 8, 24 and 48 h in dermal fibroblasts estimated by the MTT assay (the results are
showed as percent of the absorbance in control samples, mean ± SD; and lack of significance, >0.05).
Based on these results, a concentration of 100 ng per 1 mL of medium was used for future analysis,
which was both comparable to the standard therapeutic dose in patients’ blood as well as nontoxic.
The obtained gene expression results were used to perform two analyses. The first approach was
by creating clusterization with a Kohonen map (SOFM) [16], and the second by classical statistical
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analysis. The next step was to filter the set of entities for statistical significance with ANOVA, and then
evaluate the distribution of 101 (35 CYPs) from 396 mRNA (Table S1) fluorescence signals by creating
a hierarchical clusterization with Euclidean distances, using the Ward method. For this purpose,
Euclidean distances were calculated by taking two main clusters from which the left one was divided
into two sub-groups. In turn, the right one was split into four sub-clusters (Figure 2). To verify
the grouping and to choose the optimal neural network, the Davies-Bouldin value [17] (with mixed
Gaussian distribution) was calculated. For this artificial neural network, the optimal k was for
3 neurons, with a critical value of 0.9134. The distribution graph of SOFM for the selected neurons is
presented in Figure 2.
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Figure 2. Distribution of 101 (from 396) significant transcripts linked to cytochrome P450 activity in
human dermal fibroblast cells in different time of exposure to CsA. Legend: Self-organizing feature
map visualized in vertical cluster tree-entities, and in horizontal conditions (three samples per each
condition (0 control; 8, 24, 48 h CsA); heat maps show the color range of differences in classification of
normalized fluorescence signals. The values are visualized from red (high) to blue (low).
The inductive activities of CsA in the investigated fibroblasts showed in the following
distinguished transcripts: CYP19A1 (aromatase), CYP1B1 (monooxygenase), CYP2F1 (monooxygenase),
CYP7A1 (cholesterol 7α-hydroxylase) and CYP17A1 (17α-hydroxylase) (criteria: p < 0.05 and FC > 1.2
for CsA 8 h vs. 0; Table 1).
Table 1. Cytochrome P450 (CYPs) differentiating NHDFs (normal human dermal fibroblast) exposed
on CsA in various time of culture.
Gene
Symbol
Fold Change
p Value SOFM
Neuron
Biological Process
8 h vs. 0 24 h vs. 0 48 h vs. 0
CYP19A1 1.72 1.07 1.24 0.0006 2 steroids biosynthesis andmetabolism
CYP1B1 1.52 1.39 1.05 0.0030 2, 3 steroids metabolism
CYP2F1 1.26 1.18 1.09 0.0050 2 metaboli m and synthesis oflipids, cholesterol, steroids
CYP7A1 1.22 1.16 1.16 0.0330 2 steroids biosynthesis
CYP17A1 1.20 1.11 −1.04 0.0500 2 biosynthesis of cholesterol,lipids, steroids
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The neural networks showed a resemblance between CYP19A1, 2F1, 7A1 and 17A1, which took
place in the same neuron 2, as well as 1B1 (four different probes) in both (see Table 1). The 101 mRNA
from ANOVA related to CYPs was also analyzed using the post hoc Tukey’s test in all four study groups
(0, 8, 24, 48 h). The analysis gave many statistically significant mRNAs for CsA: 41 for 8 h vs. 0; 26 for
24 h vs. 0; 34 for 48 h vs. 0 (Figure 3, p ≤ 0.05). The CYPs that are mentioned in Table 1 were among
18 characteristics for 8 h vs. 0 samples.
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Table 2. Transcripts present in human dermal fibroblasts and comparison of culture with and without 
CsA in the T test and the Self‐Organizing Feature Map (SOFM) 
No.  Probe ID  Transcript  NHDFs Control (0) 
Mean [log2FS] 
NHDFs with CsA (8 h) 
Mean [log2FS]  T Test 
SOFM 
Neuron 
1  202436_s_at  1B1  12.24  12.64  ↑  2 
2  208131_s_at  8A1  12.15  12.27  NS   
3  202435_s_at  1B1  11.32  11.77  ↑  2 
4  202437_s_at  1B1  10.78  11.38  ↑  3 
5  216661_x_at  2C19/9  8.62  8.62  NS   
6  209975_at  2.E1  8.46  8.46  NS   
7  202314_at  51A1  8.39  8.85  ↑  3 
8  210726_at  3A4  7.96  8.03  NS   
i r . i r s 101 tra scri ts select s si ific t (p . ) i ’s st c
t t f li t t s t ifferent ti e of exposure to CsA.
When comparing the fluorescence signals for 91 mRNAs of cytochrome P450 (Table S2) in the
NHDF cultures with and without CsA, it was demonstrated that 31 mRNA of CYPs were up-regulated,
15 were down-regulated, and only twelve had significant changes (≤0.05, Table 2) in 8 h of exposure
compared to the control.
Those from Table 1 were found with the following up-regulated mRNA encoding
monooxygenases: 1A2, 2C19 as well as 51A1 (encode sterol 14-α demethylase) from neuron 3, which are
represented only by one out of two or three probes, respectively.
The analyses lead to distinguishing genes, which expression can influence the metabolism of CsA
in normal human dermal fibroblasts. Additionally, Table 2 is showing 47 CYPs mRNA; their presence
in human dermal fibroblast cells was already stated.
Taking into consideration all the methods used, the FC and value, and the expression of all probes,
the six CYPs (19A1, 1B1, 2F1, 7A1, 17A1 and 2D6) were distinguished. In summary, the genes have
biological significance, and directly or indirectly, are connected to biosynthesis, and/or the metabolism
of steroids.
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Table 2. Transcripts present in human dermal fibroblasts and comparison of culture with and without
CsA in the T test and the Self-Organizing Feature Map (SOFM).
No. Probe ID Transcript NHDFs Control (0)Mean [log2FS]
NHDFs with CsA (8 h)
Mean [log2FS]
t Test SOFMNeuron
1 202436_s_at 1B1 12.24 12.64 ↑ 2
2 208131_s_at 8A1 12.15 12.27 NS
3 202435_s_at 1B1 11.32 11.77 ↑ 2
4 202437_s_at 1B1 10.78 11.38 ↑ 3
5 216661_x_at 2C19/9 8.62 8.62 NS
6 209975_at 2.E1 8.46 8.46 NS
7 202314_at 51A1 8.39 8.85 ↑ 3
8 210726_at 3A4 7.96 8.03 NS
9 219825_at 26B1 7.83 7.71 NS
10 214234_s_at 3A5 7.81 7.90 NS
11 216025_x_at 2C19/9 7.75 7.60 NS
12 209148_at 2C8 7.58 7.71 NS
13 203979_at 27A1 7.49 7.62 NS
14 219565_at 20A1 7.47 7.49 NS
15 205998_x_at 3A4 6.42 6.59 NS
16 207244_x_at 2A6 6.32 6.32 NS
17 203475_at 19A1 6.25 7.04 ↑ 2
18 220432_s_at 39A1 5.47 5.52 NS
19 215103_at 2C18 5.47 5.34 NS
20 214630_at 11B2 5.25 5.34 NS
21 215982_s_at 21A2 5.23 5.33 NS
22 214419_s_at 2C9 5.16 5.10 NS
23 202434_s_at 1B1 5.16 5.50 ↑ 2
24 209976_s_at 2.E1 4.94 4.75 NS
25 207498_s_at 2D6 4.69 4.45 ↓ 1
26 216607_s_at 51A1 4.63 4.56 NS
27 1494_f_at 2A6 4.63 4.69 NS
28 220562_at 2W1 4.62 4.54 NS
29 211231_x_at 4A11 4.55 4.74 NS
30 207386_at 7B1 4.51 4.69 NS
31 205765_at 3A5 4.49 4.34 NS
32 208327_at 2A13 4.49 4.61 NS
33 211440_x_at 3A43 4.46 4.65 NS
34 210576_at 4F8 4.35 4.29 NS
35 211295_x_at 2A6 4.33 4.49 NS
36 220331_at 46A1 4.32 4.44 NS
37 210452_x_at 4F2 4.24 4.17 NS
38 207609_s_at 1A2 4.20 4.10 NS
39 206539_s_at 4F12 4.18 4.21 NS
40 214320_x_at 2A6 4.17 3.88 NS
41 204309_at 11A1 4.16 4.39 NS
42 207608_x_at 1A2 4.14 4.44 ↑ 3
43 205502_at 17A1 4.06 4.33 ↑ 2
44 1431_at 2.E1 4.01 3.67 NS
45 216058_s_at 2C19 3.17 3.40 ↑ 3
46 207406_at 7A1 2.49 2.79 ↑ 2
47 207913_at 2F1 2.51 2.86 ↑ 2
Abbreviations are as follows: Normal human dermal fibroblast (NHDF); hour (h); fluorescence signal (FS);
no significance (NS).
3. Discussion
The MTT test did not show any toxic effects of CsA in the examined concentrations on NHDFs.
The result should be considered as a positive because the selection of concentration for the experiment
was based on previous clinical experience. Hence, for the microarray experiment. the chosen amount
was a therapeutic concentration of CsA (100 ng mL−1), which occurs in the circulating blood of treated
patients [18–20]. Other findings confirm that CsA concentrations lower than 300 ng in 1 mL of medium
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are safe, not genotoxic nor mutagenic in normal human fibroblast cells (MRC-5) and did not affect
investigated cell viability and proliferation [21]. Our findings provide a preliminary in vitro study that
CsA does not have a significant influence on viability of fibroblast cells in 1–10,000 ng per mL range;
however in therapeutic concentrations it changes the expression of CYP genes.
The microarray analysis provides a large-scale look inside the analyzed cells, giving a unique
chance to understand the changes in response to CsA; our results are based on 396 transcripts in four
cultures with and without CsA. Although gene expression does not fully show the amount of the gene
product, it provides an insight into cell metabolism and indicates ongoing changes.
A number of studies which have used cell cultures, tried to explain the action and cause of side
effects of CsA: among others, excessive proliferation, diabetes, hypertension, and the increased risk of
non-melanoma skin cancers, especially squamous cell carcinoma [21–24]. A previous study proved
that steroidogenesis and CYPs are involved in the pathology of skin cancer [15]. Our experiment
used advanced statistical analysis, enabling a classification of main CYPs that may be involved in the
process of dermal fibroblasts activation. The results were analyzed with the use of neural networks
and a standard statistic method to calculate the impact of CsA on gene expression. The use of an
artificial neural network has a wide range of usage in drug research, enabling the prediction of various
processes [25]. In microarray analysis, the large amount of results can be used to create Kohonen
self-organizing maps, which give the opportunity to cluster the analyzed gene expression data,
showing possible interaction between them based on a mathematical algorithm [26]. The implemented
clusterization illustrated a relationship between them and also highlighted the influence of CsA on
the NHDF metabolism. The SOFM showed a trend in the results and indicated the resemblance in
CYP’s expression under the influence of CsA. When looking at the distribution of the listed genes
in the SOFM analysis and comparing it to their function and expression under the influence of CsA,
a pattern can be seen. The created SOFM groups are a visualization of the interaction of NHDFs with
CsA. It is visible that neuron 2 has higher fold change values in the first 8 h (Table 1), after which point
it returns to a rather normal state. Probably these genes’ products have more specific roles and are not
needed at first. As for neuron 3, the fold change of transcripts has a high level of deregulation in the
first 8 h, after which they remain at an up or down regulated level (what we can see in color differences
in Figure 2). It seems that the induced or inhibited genes could be strictly linked to a response to the
added drug. Such data correlated with the ANOVA results not only allowed the grouping of significant
genes, but also connected their expression to the effect of the drug. The distinguished genes which
were different in the first 8 h of culture were assigned to adjacent neurons 2 or 3 of the Self-Organizing
Feature Map (SOFM) (Figure 2; Tables 1 and 2) and included CYPs: 19A1, 1B1, 2F1, 7A1 and 17A1.
CYP19A1 gene product in the cell acts as an aromatase (also known as estrogen synthase or
estrogen synthetase), a key enzyme in estrogen synthesis, which is responsible for aromatization of
androgens (i.e., testosterone) into estrogens (i.e., estradiol) [27]. Similar to our findings, the presence
of 19A1 was found in the fibroblast cells [28]. Additionally, authors proved that its expression was
correlated with the estrogen level in the skin.
CYP1B1 encodes ubiquitous hydroxylase, which catalyzes the hydroxylation reaction of many
xenobiotics and endobiotics: these can be things such as drugs, environmental pollutants, lipids,
cholesterol, and/or steroid hormones (a key enzyme in androgen metabolism to estrogen and
testosterone) [6]. This gene is expressed in normal keratinocytes, melanocytes and fibroblasts as
well as in induced skin cells [9,11,29]. Its expression and activity is connected to hormones that can
induce some forms of cancer [27]. Our findings show the presence of 1B1 in the human dermal
fibroblasts, up-regulated in response to CsA.
The CYP2F1 gene is little known and encodes monooxygenase, which takes part
in steroidogenesis.
CYP7A1 encodes cholesterol 7α-hydroxylase, which is a crucial enzyme in the synthesis
and homeostasis of cholesterol [30,31]. Products of this gene (7-hydroxylases) potentially can
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produce 7-hydroxy/oxy-steroids/sterols with modifying effects on local homeostasis in the skin [14].
Our results (Tables 1 and 2) showed that CYP7A1 is significantly increased in response to CsA.
CYP17A1 mainly acts as gene coding pregnenolone and progesterone 17α hydroxylase and also
as monooxygenase takes part in other reactions of steroidogenesis as a key enzyme, and also in drugs
metabolism [6]. Its presence was found in keratinocytes and fibroblasts [30], similar to our results.
Furthermore, we found that CsA stimulates its expression in human dermal fibroblasts (Tables 1 and 2).
Genes in the third neuron of SOFM, belonging to different cytochrome P450 families such as 1A2,
2C19 and 51A1, were up-regulated (Tables 1 and 2).
CYP1A2 plays a major role in the synthesis of cholesterol, steroids and lipids in the liver [6].
Low levels or amounts below the level of detection of 1A2 were found in the skin [32]. Similar to our
findings, where CsA induced the 1A2, it was shown that coal tar increased expression of this gene in
the skin [33]. CYP2C19 is involved in xenobiotic metabolism (including medicines) and synthesis of
cholesterol, steroids and lipids [6]. Previously, its presence was found in fibroblasts [30], similar to our
findings. Additionally, our results showed an increase in expression of this gene in skin fibroblasts in
response to CsA. CYP51A1 catalyzes one of the earliest stages of cholesterol biosynthesis, namely the
C14-demethylation of lanosterol [34]. Our findings show that CsA in therapeutic concentration can
possibly induce its expression in the fibroblast cells. As indicated in the results, these transcripts are
represented only by one probe out of two or three on microarray. Thus, the mentioned results are
uncertain. CYPs are tissue-specific genes and their expression may differ.
Primarily connected with drug metabolism, in our results, CYP2D6 belongs to neuron 1 and is
down-regulated. Similar to our findings (a decrease in response to CsA), it was shown to reduce
expression of CYP2D6 in EpiDerm™ tissues relative to full thickness human buttock skin [35].
Its expression was found in different skin cells [9,32,36,37]. The presence of all the aforementioned
genes in human dermal fibroblasts has been found even in those with the weakest expression (Table 2).
In summary, the microarray analysis gives a good inside view of the cells and their reaction to the
drug. Implementing an artificial neural network by clustering gene expression signals in the analyzed
groups, and ANOVA with a post hoc test, shows that the same statistically significant genes characterize
the processes in the cell in response to a stress factor like a drug being added. The fold change 1.2–1.7
for CYP genes may not be high but still show significant p value. Additionally, we show that the
presence of highlighted CYP (19A1, 1B1, 2F1, 7A1, 17A1, 2D6) in all probes on the microarray can
enhance confidence to the result.
The limitation of this study is that only one type of skin cell was analyzed. It would be necessary
to study keratinocytes and melanocytes in response to CsA, as it would give us a wide view of
the entire skin tissue. On the other hand, this study can be advantageous, because the group is
highly homogeneous. Moreover, it only affects a single view of the response to the drug and is
less complicated.
An additional limitation is the lack of validation of highlighted genes for individual time to CsA
exposition by using another method. However, each gene has already been mentioned or analyzed in
other studies that were discussed previously. The presence of some of these genes has been proven in
fibroblasts, but not all; therefore, our findings are the first covering the entire profile of CYP genes in
human dermal fibroblasts.
Another limitation, but perhaps an advantage, is that the analysis of the microarrays concerns
only the panel of CYPs, without genes connected or influencing their activity. Those genes are not
analyzed, because they would not be significant to the results (single significant transcript between two
or three, i.e., as for CYP2C19). For example, in the cases shown in Figure 2, the transcription factors:
NFAT5 (nuclear factor of activated T-cells 5), NR2E3 (nuclear receptor 2 subfamily 2 group E member 3,
negatively regulating transcription) and FOXA2 (forkhead box a2, positively regulating transcription)
that belong to neuron 2, hybridized with one out of the two probes present on the microarray. The same
problem applies to KLF9 (Kruppel-like factor 9); namely two out of three transcripts had showed
reverse regulation, despite FOXA2 being a 1B1, 2F1, 7A1, 17A1 transcription factor and KLF regulating
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19A1. Their influence cannot be estimated based on the regulation of the highlighted CYP genes
transcription or due to their own increase or decrease, under the influence of CsA. The distribution
of 396 transcripts related to cytochrome P450 led us to select only one main pathway activated by
CsA in skin fibroblasts, which was steroidogenesis. The main purpose of our work was to select
the CYP genes, which plays a major role in response to CsA in human dermal fibroblasts, and this
goal has been realized. Furthermore, we can conclude that the expression profile of cytochrome P450
in human dermal fibroblasts changes in response to CsA exposition in therapeutic concentration,
especially affecting genes linked to steroid synthesis and/or metabolism. One of these pathways may
be directly or indirectly responsible for the development of non-melanoma skin cancer in transplant
recipients who have been using cyclosporin A for many years. Could steroids be the cause? Or is the
reason an increased amount of free radicals formed during the induced reactions of steroid synthesis
and/or metabolism? It may be both. To answer these questions, further studies are needed.
4. Materials and Methods
4.1. Cell Culture
Normal human dermal fibroblasts-adult (NHDF-Ad, CC-2511, CloneticsTM, Lonza, Basel,
Switzerland) were cultured in sterile flasks of 25 cm2 surface with angled neck and antibacterial
filters (Nunc®; Sigma-Aldrich, Saint Louis, MO, USA) in initial cell density 3500 on 1 cm2. The cells
were passaged on the sixth day and observed microscopically. To obtain a confluent monolayer,
the cells were cultured in a basal fibroblast growth medium (CC-3131, FGMTM, Lonza) and then in a
medium with standard supplements, (CC-3132, Lonza) according to the obtained producer protocol.
The cell cultures were maintained at 37 ◦C, enriched with 5% CO2 of air atmosphere with constant
humidity. Cells were counted microscopically in a haemocytometer.
4.2. Cell Viability
The cultured NHDF-Ad (CC-2511, Lonza, Basel, Switzerland) in confluent phase of growth
and at a final number of 2 × 103 cells per 1 well were used for the test. The cells were
seeded in 96-well plates to which CsA was added at a concentration range from 1.0 to 10,000 ng
per 1 mL of the medium (Sandimmun, Novartis, Basel, Switzerland) and cultured for 8, 24,
48 h in standard conditions. Each procedure included a two blank sample with a fresh
medium with and without cells. After incubation time the viability assay was performed using
3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) according to the standard
producer’s protocol (M2128; Sigma-Aldrich). After 4 h of incubation with dye and liberation of the
incorporated dye, absorbance was measured at λ = 570 nm and λ = 690 nm (reference wavelength) [38]
using the MRX Revelation plate reader (Dynex Technologies, Chantilly, VA, USA). The viability test
was repeated three times and there were eight replicates for each concentration of CSA.
4.3. Cell Culture with CsA
NHDFs (CC-2511, Lonza) were cultured in a liquid fibroblast growth medium (3132, Lonza)
according to the protocol. After the confluent phase, CsA (Sandimmun, Novartis) was added to the
medium at a selected concentration of 100 ng per 1 mL. The NHDFs were cultured for 8, 24 and
48 h and after each time period, the total cells were rinsed three times and harvested, then used to
isolate RNA.
4.4. RNA Isolation
After each time period total cell RNA was isolated with the use of TRIzol reagent in accordance
with the producer’s protocol (Invitrogen, Carlsbad, CA, USA). Isolated RNA was purified with
RNeasy Mini Kit columns (Qiagen, Hilden, Germany). The purity of the RNA was evaluated
spectrophotometrically and by using electrophoresis.
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4.5. Microarray HGU-133A_2.0 Analysis
Eight micrograms of pure RNA were obtained and were used for preparing one microarray.
Analysis was performed by cDNA and cRNA synthesis; its fragmentation and hybridization were
analyzed with HG-U133A_2.0 microarrays according to the Gene Expression Analysis Technical
Manual (Affymetrix, Santa Clara, CA, USA). The fluorescence intensity signal was measured
using GeneArray Scanner 3000 7G (Affymetrix). During all stages, the quality of cDNA and
cRNA was controlled by performing agarose electrophoresis (1%) and by absorbance measure
in λ 230/260/280 nm using spectrophotometric calculator GeneQuant II (Pharmacia Biotech,
Uppsala, Sweden).
All data from performed microarrays are deposited in PL-Grid Infrastructure (www.plgrid.pl/en).
4.6. Statistical Analysis
The cell viability results were analyzed with descriptive statistics (mean and standard deviation)
and analysis of variance (ANOVA) test (with statistical significance p ≤ 0.05). The fluorescence
signals of the 396 mRNAs obtained from cultured NHDFs with and without CsA were subjected
to statistical analysis using STATISTICA 12 (StatSoft, Kraków, Poland), MATLAB 2011 (MathWorks,
Natick, MA, USA) and GeneSpring 13.0 (Agilent Technologies, Inc., Santa Clara, CA, USA) software.
Additionally, to achieve the goal of the study, we decided to use self-organizing maps of artificial
neural networks to analyze the CYP’s among the genes linked to cytochrome P450.
The data were grouped according to the time of culturing NHDFs without (0) and with CsA
(8, 24, 48 h). The clusterization process and neural networks were made for groups of 396 mRNA
(Table S1) in which there were 91 CYPs (Table S2) and linked mRNAs that have a crucial impact
on its functioning (Affymetrix NetAffx database, www.affymetrix.com). The mRNA fluorescence
signals were normalized by the RMA (Robust Multichip Average; RMAExpress) method and then
used in clusterization with Euclidean distance using the Ward method (STATISTICA 12) to analyze
these 396 probe sets. Afterwards, the analyzed mRNA in all four groups (0, 8, 24 and 48 h) were
subjected to the creation of an artificial neural network. The neural network, by choice, was the
self-organizing feature map (SOFM, or Kohonen map) [16], which was trained by unsupervised
learning in STATISTICA 12. An analytical estimation of SOFM grouping quality was made using the
Davies-Bouldin algorithm [17], which was calculated in MATLAB 2011 version.
The standard statistical analysis was performed in GeneSpring 13.0, where descriptive statistics
were calculated for all 396 mRNA with 91 CYPs in each group (0, 8, 24 and 48 h) and analyzed using
ANOVA with the post hoc Tukey test. The significance level was set at p ≤ 0.05. From statistically
significant mRNAs (p ≤ 0.05) with a fold change parameter (FC > 1.2) greater than 1.2 had
been distinguished.
5. Conclusions
On the basis of microarray analysis of the investigated NHDF cells, CsA induces the expression of
CYP19A1, 1B1, 7A1, 2F1, 17A1 and inhibits the 2D6 gene, and it can be concluded that CsA changes the
expression of CYP genes, which can take part in steroidogenesis. Increased expression of CYP genes
related to steroid synthesis and/or metabolism under the influence of CsA shows the mechanism of its
acting in human dermal fibroblast cells.
Supplementary Materials: The following are available online, Table S1: List of 396 ID mRNA and gene symbols
used in the experiment; Table S2: List of 91 ID mRNA and gene symbols used in the experiment.
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